Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

References 222

1. 1.

   Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140-6.

   Not in our library10.1016/j.molonc.2012.01.010 (opens in a new tab)

2. 2.

   Pandha HS, Waxman J, Sikora K. Tumour markers. Br J Hosp Med. 1994;51(6):297-303.

   Not in our library

3. 3.

   He Yanli, Lu Haijun, Zhang Lijuan. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases. Prog Mol Biol Transl Sci. 2019;162:199-212.

   Not in our library10.1016/bs.pmbts.2019.01.001 (opens in a new tab)

4. 4.

   Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-84.

   Not in our library10.1016/s0140-6736(11)60993-8 (opens in a new tab)

5. 5.

   Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;(11):1491-1505.

   Not in our library10.1016/j.annonc.2020.07.014 (opens in a new tab)

6. 6.

   Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, Verhaak RG. The landscape and therspeutic relevance of cancer-associated transcript. Oncogene. 2015;34(37):4845-54.

   Not in our library10.1038/onc.2014.406 (opens in a new tab)

7. 7.

   Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023.

   Not in our library10.1056/nejmoa2308795 (opens in a new tab)

8. 8.

   Varkaris A, Pazolli E, Gunaydin H, Wang Q, Pierce L, Boezio AA, DiPietro L, Frost A, Giordanetto F, Hamilton EP, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia. Cancer DIscov. 2023.

   Not in our library10.1158/2159-8290.cd-23-0944 (opens in a new tab)

9. 9.

   Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058-2070.

   Not in our library10.1056/nejmoa2214131 (opens in a new tab)

10. 10.

    Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-5.

    Not in our library10.1158/0008-5472.can-06-0191 (opens in a new tab)

11. 11.

    Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, et al. Encorafenib, Binimetinib, and Cetuximab in BRAFV600E-Mutated Colorectal Cancer. N Engl J Med. 2019;381(17):1632-1643.

    Not in our library10.1056/nejmoa1908075 (opens in a new tab)

12. 12.

    Planchard D, Jänne PA, Cheng Y, Yang JC, Yanagitani N, Kim SW, Sugawara S, Yu Y, Fan Y, Geater SL, Laktionov K, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935-1948.

    Not in our library10.1056/nejmoa2306434 (opens in a new tab)

13. 13.

    Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018;378(8):731-739.

    Not in our library10.1056/nejmoa1714448 (opens in a new tab)

14. 14.
    Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial · 2023

    No notice
15. 15.

    Harms PW, Frankel TL, Moutafi M, Rao A, Rimm DL, Taube JM, Thomas D, Chan MP, Pantanowitz L. Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists. Mod Pathol. 2023;36(7):100197.

    Not in our library10.1016/j.modpat.2023.100197 (opens in a new tab)

16. 16.

    Cohen R, Lee-Pullen T, Miller TJ, Meehan K, Fuller K, McCoy MJ. Optimising multiplex immunofluorescence staining for characterising the tumour immune micro-environment. Methods. 2023;219:48-57.

    Not in our library10.1016/j.ymeth.2023.09.004 (opens in a new tab)

17. 17.

    Francisco-Cruz A, Parra ER, Tetzlaff MT, Wistuba II. Multiplex Immunofluorescence Assays Methods. Mol Biol. 2020;2055:467-495.

    Not in our library10.1007/978-1-4939-9773-2_22 (opens in a new tab)

18. 18.

    Barrow E, Evans DG, McMahon R, Hill J, Byers R. A comparative study of quantitative immunohistochemistry and quantum dot immunohistochemistry for mutation carrier identification in Lynch syndrome. J Clin Pathol. 2010;64(3):208-14.

    Not in our library10.1136/jcp.2010.084418 (opens in a new tab)

19. 19.

    Dowlatshahi S, Abdekhodaie MJ. Electrochemical prostate-specific antigen biosensors based on electroconductive nanomaterials and polymers. Clin Chim Acta. 2021;516:111-135.

    Not in our library10.1016/j.cca.2021.01.018 (opens in a new tab)

20. 20.

    Laraib U, Sargazi S, Rahdar A, Khatami M, Pandey S. Nanotechnology-based approaches for effective detection of tumor markers: A comprehensive state-of-the-art review. Int J Biol Macromol. 2022;195:356-383.

    Not in our library10.1016/j.ijbiomac.2021.12.052 (opens in a new tab)

21. 21.

    Miedema J, Andea AA. Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis. Mod Pathol. 2020;33(7):1318-1330.

    Not in our library10.1038/s41379-020-0490-7 (opens in a new tab)

22. 22.

    Galogre M, Rodin D, Pyatnitskiy M, Mackelprang M, Koman I. A review of HER2 overexpression and somatic mutations in cancers. Crit Rev Oncol Hematol. 2023;186:103997.

    Not in our library10.1016/j.critrevonc.2023.103997 (opens in a new tab)

23. 23.

    Cen S, Liu Z, Pan H, Han W. Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188605.

    Not in our library10.1016/j.bbcan.2021.188605 (opens in a new tab)

24. 24.

    Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33-48.

    Not in our library10.1038/s41571-019-0268-3 (opens in a new tab)

25. 25.

    Kruglyak KM, Lin E, Ong FS. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer. Adv Exp Med Biol. 2016;890:123-36.

    Not in our library10.1007/978-3-319-24932-2_7 (opens in a new tab)

26. 26.

    Paolillo C, Londin E, Fortina P. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine. Scand J Clin Lab Invest Suppl. 2016;245:S84-91.

    Not in our library10.1080/00365513.2016.1210331 (opens in a new tab)

27. 27.
    Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review · 2020

    No notice
28. 28.

    Oliveira LJC, Amorim LC, Megid TBC, de Resende CAA, Mano MS. Gene expression signatures in early breast cancer: Better together with clinicopathological features. Crit Rev Oncol Hematol. 2022;175:103708.

    Not in our library10.1016/j.critrevonc.2022.103708 (opens in a new tab)

29. 29.

    Zeng C, Zhang J. A narrative review of five multigenetic assays in breast cancer. Transl Cancer Res. 2022;11(4):897-907.

    Not in our library10.21037/tcr-21-1920 (opens in a new tab)

30. 30.

    Reck M, Remon J, Hellmann MD. First-line immunotherapy for non-small-cell lung cancer. J Clin Oncol. 2022;40:586-597.

    Not in our library10.1200/jco.21.01497 (opens in a new tab)

31. 31.

    Passaro A, Brahmer J, Antonia S, Mok T, Peters S. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies. J Clin Oncol. 2022;40:598-610.

    Not in our library10.1200/jco.21.01845 (opens in a new tab)

32. 32.

    Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18:345-362.

    Not in our library10.1038/s41571-021-00473-5 (opens in a new tab)

33. 33.

    Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353-1365.

    Not in our library10.1016/s1470-2045(20)30445-9 (opens in a new tab)

34. 34.

    Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-1985.

    Not in our library10.1056/nejmoa2202170 (opens in a new tab)

35. 35.

    Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber W-J, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515:577-581.

    Not in our library10.1038/nature13988 (opens in a new tab)

36. 36.

    van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerk B, van Dijk LJA, Behjati S, Hilkmann H, el Atmioui D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013;31:e439-e442.

    Not in our library10.1200/jco.2012.47.7521 (opens in a new tab)

37. 37.

    Parkhurst MR, Robbins PF, Tran E, Prickett TD, Gartner JJ, Jia L, Ivey G, Li YF, El-Gamil M, Lalani A, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discov. 2019;9:1022-1035.

    Not in our library10.1158/2159-8290.cd-18-1494 (opens in a new tab)

38. 38.

    Linnemann C, van Buuren MM, Bies L, Verdegaal EME, Schotte R, Calis JJA, Behjati S, Velds A, Hilkmann H, el Atmioui D, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015;21:81-85.

    Not in our library10.1038/nm.3773 (opens in a new tab)

39. 39.

    Robbins PF, Lu Y-C, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19:747-752.

    Not in our library10.1038/nm.3161 (opens in a new tab)

40. 40.

    Tran E, Ahmadzadeh M, Lu Y-C, Gros A, Turcotte S, Robbins PF, Gartner JJ, Zheng Z, Li YF, Ray S, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science. 2015;350:1387-1390.

    Not in our library10.1126/science.aad1253 (opens in a new tab)

41. 41.

    Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016;22:433-438.

    Not in our library10.1038/nm.4051 (opens in a new tab)

42. 42.

    Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, Arthur CD, White JM, Chen Y-S, Shea LK, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482:400-404.

    Not in our library10.1038/nature10755 (opens in a new tab)

43. 43.

    Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science. 2015;348:124-128.

    Not in our library10.1126/science.aaa1348 (opens in a new tab)

44. 44.

    Castle JC, Kreiter S, Diekmann J, Löwer M, van de Roemer N, de Graaf J, Selmi A, Diken M, Boegel S, Paret C, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72:1081-1091.

    Not in our library10.1158/0008-5472.can-11-3722 (opens in a new tab)

45. 45.

    Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189-2199.

    Not in our library10.1056/nejmoa1406498 (opens in a new tab)

46. 46.

    Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Foppen MHG, Goldinger SM, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207-211.

    Not in our library10.1126/science.aad0095 (opens in a new tab)

47. 47.

    Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909-1920.

    Not in our library10.1016/s0140-6736(16)00561-4 (opens in a new tab)

48. 48.

    Alexandrov LB, Australian Pancreatic Cancer Genome Initiative, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-421.

    Not in our library10.1038/nature12477 (opens in a new tab)

49. 49.

    Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, Philip R, Ghosh S, Theoret MR, Beaver JA, et al. FDA approval summary: Pembrolizumab for the treatment of tumor mutational burden–high solid tumors. Clin Cancer Res. 2021;27:4685-4689.

    Not in our library10.1158/1078-0432.ccr-21-0327 (opens in a new tab)

50. 50.

    Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M-J, van den Heuvel MM, Cobo M, Vicente D, Smolin A, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non–small cell lung cancer. JAMA Oncol. 2020;6:661.

    Not in our library10.1001/jamaoncol.2020.0237 (opens in a new tab)

51. 51.

    Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, et al. Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. N Engl J Med. 2020;383:1328-1339.

    Not in our library10.1056/nejmoa1917346 (opens in a new tab)

52. 52.

    Socinski M, Velcheti V, Mekhail T, Chae YK, Leal TA, Dowell JE, Tsai ML, Dakhil CS, Stella P, Shen V, et al. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Ann Oncol. 2019;30:v919-v920.

    Not in our library

53. 53.

    Raiber-Moreau E-A, Portella G, Butler MG, Clement O, Konigshofer Y, Hadfield J. Development and validation of blood tumor mutational burden reference standards. Genes Chromosomes Cancer. 2023;62:121-130.

    Not in our library10.1002/gcc.23100 (opens in a new tab)

54. 54.

    Merino DM, McShane LM, Fabrizio D, Funari V, Chen S-J, White JR, Wenz P, Baden J, Barrett JC, Chaudhary R, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. 2020;8:e000147.

    Not in our library10.1136/jitc-2019-000147 (opens in a new tab)

55. 55.

    McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-1469.

    Not in our library10.1126/science.aaf1490 (opens in a new tab)

56. 56.
    Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition · 2021

    No notice
57. 57.

    Turajlic S, Litchfield K, Xu H, Rosenthal R, McGranahan N, Reading JL, Wong YNS, Rowan A, Kanu N, Al Bakir M, et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncol. 2017;18:1009-1021.

    Not in our library10.1016/s1470-2045(17)30516-8 (opens in a new tab)

58. 58.

    Fratta E, Coral S, Covre A, Parisi G, Colizzi F, Danielli R, Marie Nicolay HJ, Sigalotti L, Maio M. The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. Mol Oncol. 2011;5:164-182.

    Not in our library10.1016/j.molonc.2011.02.001 (opens in a new tab)

59. 59.

    Knuth A, Danowski B, Oettgen HF, Old LJ. T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci USA. 1984;81:3511-3515.

    Not in our library10.1073/pnas.81.11.3511 (opens in a new tab)

60. 60.

    Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810-11813.

    Not in our library10.1073/pnas.92.25.11810 (opens in a new tab)

61. 61.

    Jin S, Cao S, Li J, Meng Q, Wang C, Yao L, Lang Y, Cao J, Shen J, Pan B, et al. Cancer/testis antigens (CTAs) expression in resected lung cancer. Onco Targets Ther. 2018;11:4491-4499.

    Not in our library10.2147/ott.s159491 (opens in a new tab)

62. 62.

    Djureinovic D, Hallström BM, Horie M, Mattsson JSM, La Fleur L, Fagerberg L, Brunnström H, Lindskog C, Madjar K, Rahnenführer J, et al. Profiling cancer testis antigens in non–small-cell lung cancer. JCI Insight. 2016;1.

    Not in our library10.1172/jci.insight.86837 (opens in a new tab)

63. 63.

    Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:822-835.

    Not in our library10.1016/s1470-2045(16)00099-1 (opens in a new tab)

64. 64.

    Marchand M, van Baren N, Weynants P, Brichard V, Dréno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer. 1999;80:219-230.

    Not in our library10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>3.0.co;2-s (opens in a new tab)

65. 65.

    Parvizpour S, Razmara J, Pourseif MM, Omidi Y. In silico design of a triple-negative breast cancer vaccine by targeting cancer testis antigens. BioImpacts. 2019;9:45-56.

    Not in our library10.15171/bi.2019.06 (opens in a new tab)

66. 66.

    Sebastian M, Schröder A, Scheel B, Hong HS, Muth A, von Boehmer L, Zippelius A, Mayer F, Reck M, Atanackovic D, et al. A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunol Immunother. 2019;68:799-812.

    Not in our library10.1007/s00262-019-02315-x (opens in a new tab)

67. 67.

    Mao Y, Fan W, Hu H, Zhang L, Michel J, Wu Y, Wang J, Jia L, Tang X, Xu L, et al. MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. J Hematol Oncol. 2019;12.

    Not in our library10.1186/s13045-019-0793-7 (opens in a new tab)

68. 68.
    Novel TCR-like CAR-T cells targeting an HLA∗0201-restricted SSX2 epitope display strong activity against acute myeloid leukemia · 2021

    Not checked
69. 69.

    Calles A, Riess JW, Brahmer JR. Checkpoint blockade in lung cancer with driver mutation: Choose the road wisely. Am Soc Clin Oncol Educ Book. 2020;372-384.

    Not in our library10.1200/edbk_280795 (opens in a new tab)

70. 70.

    Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Lung Cancer. 2018;115:12-20.

    Not in our library10.1016/j.lungcan.2017.11.009 (opens in a new tab)

71. 71.

    Dong Z-Y, Zhang J-T, Liu S-Y, Su J, Zhang C, Xie Z, Zhou Q, Tu H-Y, Xu C-R, Yan L-X, et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology. 2017;6:e1356145.

    Not in our library10.1080/2162402x.2017.1356145 (opens in a new tab)

72. 72.

    Streicher K, Higgs BW, Wu S, Coffman K, Damera G, Durham N, Greenlees L, Lazdun Y, Cheng L, Cooper Z, et al. Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC. J Clin Oncol. 2017;35:11505.

    Not in our library

73. 73.
    PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis · 2017

    No notice
74. 74.

    Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, et al. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thor Oncol. 2021;16(4):583-600.

    Not in our library10.1016/j.jtho.2020.12.010 (opens in a new tab)

75. 75.
    The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs · 2015

    No notice
76. 76.

    Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014;25:1935-1940.

    Not in our library10.1093/annonc/mdu242 (opens in a new tab)

77. 77.

    D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112:95-102.

    Not in our library10.1038/bjc.2014.555 (opens in a new tab)

78. 78.

    Schoenfeld AJ, Rizvi H, Bandlamudi C, Sauter JL, Travis WD, Rekhtman N, Plodkowski AJ, Perez-Johnston R, Sawan P, Beras A, et al. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. Ann Oncol. 2020;31:599-608.

    Not in our library10.1016/j.annonc.2020.01.065 (opens in a new tab)

79. 79.

    Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29:2085-2091.

    Not in our library10.1093/annonc/mdy334 (opens in a new tab)

80. 80.

    Dong Z-Y, Zhong W-Z, Zhang X-C, Su J, Xie Z, Liu S-Y, Tu H-Y, Chen H-J, Sun Y-L, Zhou Q, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23:3012-3024.

    Not in our library10.1158/1078-0432.ccr-16-2554 (opens in a new tab)

81. 81.

    Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, et al. Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol. 2022;17:399-410.

    Not in our library10.1016/j.jtho.2021.10.013 (opens in a new tab)

82. 82.

    Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822-835.

    Not in our library10.1158/2159-8290.cd-18-0099 (opens in a new tab)

83. 83.

    Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al. Loss of PTEN promotes resistance to T cell–mediated immunotherapy. Cancer Discov. 2016;6:202-216.

    Not in our library10.1158/2159-8290.cd-15-0283 (opens in a new tab)

84. 84.

    Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, et al. PTEN loss confers resistance to anti–PD-1 therapy in non–small cell lung cancer by increasing tumor infiltration of regulatory T cells. Cancer Res. 2023;83:2513-2526.

    Not in our library10.1158/0008-5472.can-22-3023 (opens in a new tab)

85. 85.

    Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35-44.

    Not in our library10.1016/j.cell.2016.02.065 (opens in a new tab)

86. 86.
    Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer · 2016

    No notice
87. 87.

    Colebatch A, Hitchins M, Williams R, Meagher A, Hawkins NJ, Ward RL. The role of MYH and microsatellite instability in the development of sporadic colorectal cancer. Br J Cancer. 2006;95:1239-1243.

    Not in our library10.1038/sj.bjc.6603421 (opens in a new tab)

88. 88.

    Ready N, Farago AF, de Braud F, Atmaca A, Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14:237-244.

    Not in our library10.1016/j.jtho.2018.10.003 (opens in a new tab)

89. 89.

    Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381:2020-2031.

    Not in our library10.1056/nejmoa1910231 (opens in a new tab)

90. 90.

    Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G, Srimuninnimit V, Laktionov KK, Bondarenko I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819-1830.

    Not in our library10.1016/s0140-6736(18)32409-7 (opens in a new tab)

91. 91.

    Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, Turk HM, Cicin I, Bentsion D, Gladkov O, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592-604.

    Not in our library10.1016/s0140-6736(21)00228-2 (opens in a new tab)

92. 92.

    Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24:1441-1448.

    Not in our library10.1038/s41591-018-0134-3 (opens in a new tab)

93. 93.

    Thompson JC, Davis C, Deshpande C, Hwang W-T, Jeffries S, Huang A, Mitchell TC, Langer CJ, Albelda SM. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J Immunother Cancer. 2020;8:e000974.

    Not in our library10.1136/jitc-2020-000974 (opens in a new tab)

94. 94.

    Wang H, Liu B, Wei J. Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy. Cancer Lett. 2021;517:96-104.

    Not in our library10.1016/j.canlet.2021.06.008 (opens in a new tab)

95. 95.
    Resistance to checkpoint blockade therapy through inactivation of antigen presentation · 2017

    No notice
96. 96.

    Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819-829.

    Not in our library10.1056/nejmoa1604958 (opens in a new tab)

97. 97.

    Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, et al. Impaired HLA Class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7:1420-1435.

    Not in our library10.1158/2159-8290.cd-17-0593 (opens in a new tab)

98. 98.

    Rosenthal R, The TRACERx consortium, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479-485.

    Not in our library10.1038/s41586-019-1032-7 (opens in a new tab)

99. 99.
    Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution · 2017

    No notice
100. 100.

     Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol. 1997;15:563-591.

     Not in our library10.1146/annurev.immunol.15.1.563 (opens in a new tab)

101. 101.

     Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.

     Not in our library10.1038/nrc3239 (opens in a new tab)

102. 102.

     Ribas A. Adaptive immune resistance: How cancer protects from immune attack. Cancer Discov. 2015;5:915-919.

     Not in our library10.1158/2159-8290.cd-15-0563 (opens in a new tab)

103. 103.

     Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7:188-201.

     Not in our library10.1158/2159-8290.cd-16-1223 (opens in a new tab)

104. 104.

     Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell. 2016;167:397-404.

     Not in our library10.1016/j.cell.2016.08.069 (opens in a new tab)

105. 105.
     Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions · 2017

     No notice
106. 106.

     Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008;27:5904-5912.

     Not in our library10.1038/onc.2008.271 (opens in a new tab)

107. 107.

     Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30:R921-R925.

     Not in our library10.1016/j.cub.2020.06.081 (opens in a new tab)

108. 108.

     Schalper KA, Brown J, Carvajal-Hausdorf D, McLaughlin J, Velcheti V, Syrigos KN, Herbst RS, Rimm DL. Objective measurement and clinical significance of TILs in non–small cell lung cancer. J Natl Cancer Inst. 2015;107.

     Not in our library10.1093/jnci/dju435 (opens in a new tab)

109. 109.
     Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis. · 2020

     Not checked
110. 110.

     Shepherd DJ, Tabb ES, Kunitoki K, Zhang ML, Kem M, Barth J, Qualls DA, Mooradian MJ, Gainor JF, Mino-Kenudson M, et al. Lymphocyte-activation gene 3 in non-small-cell lung carcinomas: correlations with clinicopathologic features and prognostic significance. Mod Pathol. 2022;35:615-624.

     Not in our library10.1038/s41379-021-00974-9 (opens in a new tab)

111. 111.

     Shirasawa M, Yoshida T, Imabayashi T, Okuma K, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, et al. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. Eur J Cancer. 2022;162:1-10.

     Not in our library10.1016/j.ejca.2021.11.013 (opens in a new tab)

112. 112.

     Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, Mitani S, Matsumoto Y, Masuda K, Shinno Y, et al. Differential immune-related microenvironment determines programmed cell death protein-1/programmed death-ligand 1 blockade efficacy in patients with advanced NSCLCJ. Thorac Oncol. 2021;16:2078-2090.

     Not in our library10.1016/j.jtho.2021.07.027 (opens in a new tab)

113. 113.

     Uryvaev A, Passhak M, Hershkovits D, Sabo E, Bar-Sela G. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. Med Oncol. 2018;35:25.

     Not in our library10.1007/s12032-018-1080-0 (opens in a new tab)

114. 114.

     Rakaee M, Adib E, Ricciuti B, Sholl LM, Shi W, Alessi JV, Cortellini A, Fulgenzi CAM, Viola P, Pinato DJ, et al. Association of machine learning–based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC. JAMA Oncol. 2023;9:51.

     Not in our library10.1001/jamaoncol.2022.4933 (opens in a new tab)

115. 115.
     Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy · 2018

     Corrected
116. 116.

     Niemeijer A-LN, Sahba S, Smit EF, Lissenberg-Witte BI, de Langen AJ, Thunnissen E. Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy. Br J Cancer. 2020;123:392-402.

     Not in our library10.1038/s41416-020-0888-5 (opens in a new tab)

117. 117.

     Hashemi S, Fransen MF, Niemeijer A, Ben Taleb N, Houda I, Veltman J, Becker-Commissaris A, Daniels H, Crombag L, Radonic T, et al. Surprising impact of stromal TIL’s on immunotherapy efficacy in a real-world lung cancer study. Lung Cancer. 2021;153:81-89.

     Not in our library10.1016/j.lungcan.2021.01.013 (opens in a new tab)

118. 118.

     Althammer S, Tan TH, Spitzmüller A, Rognoni L, Wiestler T, Herz T, Widmaier M, Rebelatto MC, Kaplon H, Damotte D, et al. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy. J Immunother Cancer. 2019;7:121.

     Not in our library10.1186/s40425-019-0589-x (opens in a new tab)

119. 119.

     Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, Theelen WSME, Koelzer VH, Mertz KD, Zippelius A, et al. PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. Clin Cancer Res. 2022;28:4893-4906.

     Not in our library10.1158/1078-0432.ccr-22-0992 (opens in a new tab)

120. 120.

     Yeong J, Suteja L, Simoni Y, Lau KW, Tan AC, Li HH, Lim S, Loh JH, Wee FYT, Nerurkar SN, et al. Intratumoral CD39+CD8+ T cells predict response to programmed cell death protein-1 or programmed death ligand-1 blockade in patients with NSCLC. J Thorac Oncol. 2021;16:1349-1358.

     Not in our library10.1016/j.jtho.2021.04.016 (opens in a new tab)

121. 121.

     Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26:259-271.

     Not in our library10.1093/annonc/mdu450 (opens in a new tab)

122. 122.

     Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485-498.

     Not in our library10.1038/s41577-020-00490-y (opens in a new tab)

123. 123.

     Casanova-Acebes M, Dalla E, Leader AM, LeBerichel J, Nikolic J, Morales BM, Brown M, Chang C, Troncoso L, Chen ST, et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature. 2021;595:578-584.

     Not in our library10.1038/s41586-021-03651-8 (opens in a new tab)

124. 124.

     Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009;33:118-126.

     Not in our library10.1183/09031936.00065708 (opens in a new tab)

125. 125.

     Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21:799-820.

     Not in our library10.1038/s41573-022-00520-5 (opens in a new tab)

126. 126.

     Koh J, Hur JY, Lee KY, Kim MS, Heo JY, Ku BM, Sun J-M, Lee S-H, Ahn JS, Park K, et al. Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci Rep. 2020;10.

     Not in our library10.1038/s41598-020-76130-1 (opens in a new tab)

127. 127.

     Milette S, Fiset PO, Walsh LA, Spicer JD, Quail DF. The innate immune architecture of lung tumors and its implication in disease progression. J Pathol. 2019;247:589-605.

     Not in our library10.1002/path.5241 (opens in a new tab)

128. 128.

     Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N. Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer. 2021;9:e002242.

     Not in our library10.1136/jitc-2020-002242 (opens in a new tab)

129. 129.

     Kargl J, Zhu X, Zhang H, Yang GHY, Friesen TJ, Shipley M, Maeda DY, Zebala JA, McKay-Fleisch J, Meredith G, et al. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight. 2019;4.

     Not in our library10.1172/jci.insight.130850 (opens in a new tab)

130. 130.

     Jin J, Yang L, Liu D, Li W. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open. 2020;10:e035031.

     Not in our library10.1136/bmjopen-2019-035031 (opens in a new tab)

131. 131.

     Yang T, Hao L, Yang X, Luo C, Wang G, Lin Cai C, Qi S, Li Z. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis. BMJ Open. 2021;11:e049123.

     Not in our library10.1136/bmjopen-2021-049123 (opens in a new tab)

132. 132.

     Amaral SR, Casal Moura M, Carvalho J, Chaves A, Jesus E, Sousa G. Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. Ann Oncol. 2019;30:i3.

     Not in our library

133. 133.
     Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors · 2021

     No notice
134. 134.

     Uematsu M, Narita K, Sato T, Hosomi Y. Peripheral blood eosinophil count optimizes pembrolizumab-based immunotherapy in the first-line setting of advanced or recurrent non-small cell lung cancer. Research Square. 2021.

     Not in our library10.21203/rs.3.rs-967835/v1 (opens in a new tab)

135. 135.

     Alves A, Dias M, Campainha S, Barroso A. Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy. J Thorac Dis. 2021;13:2716-2727.

     Not in our library10.21037/jtd-20-3525 (opens in a new tab)

136. 136.

     Giommoni E, Giorgione R, Paderi A, Pellegrini E, Gambale E, Marini A, Antonuzzo A, Marconcini R, Roviello G, Matucci-Cerinic M, et al. Eosinophil count as predictive biomarker of immune-related adverse events (irAEs) in immune checkpoint inhibitors (ICIs) therapies in oncological patients. Immuno. 2021;1:253-263.

     Not in our library

137. 137.

     Blomberg OS, Spagnuolo L, Garner H, Voorwerk L, Isaeva OI, van Dyk E, Bakker N, Chalabi M, Klaver C, Duijst M, et al. IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell. 2023;41:106-123.

     Not in our library10.1016/j.ccell.2022.11.014 (opens in a new tab)

138. 138.

     Ott PA, Bang Y-J, Piha-Paul SA, Razak ARA, Bennouna J, Soria J-C, Rugo HS, Cohen RB, O’Neil BH, Mehnert JM, et al. T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37:318-327.

     Not in our library10.1200/jco.2018.78.2276 (opens in a new tab)

139. 139.

     Higgs BW, Morehouse CA, Streicher K, Brohawn PZ, Pilataxi F, Gupta A, Ranade K. Interferon gamma messenger RNA signature in tumor biopsies predicts outcomes in patients with non–small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin Cancer Res. 2018;24:3857-3866.

     Not in our library10.1158/1078-0432.ccr-17-3451 (opens in a new tab)

140. 140.
     The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort · 2019

     No notice
141. 141.
     Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer · 2020

     No notice
142. 142.
     Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer · 2022

     Not checked
143. 143.

     Jang H-J, Lee H-S, Ramos D, Park IK, Kang CH, Burt BM, Kim YT. Transcriptome-based molecular subtyping of non–small cell lung cancer may predict response to immune checkpoint inhibitors. J Thorac Cardiovasc Surg. 2020;159:1598-1610.

     Not in our library10.1016/j.jtcvs.2019.10.123 (opens in a new tab)

144. 144.
     A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma · 2021

     Not checked
145. 145.

     Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837-1846.

     Not in our library10.1016/s0140-6736(16)00587-0 (opens in a new tab)

146. 146.

     Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 2018;19:737-746.

     Not in our library10.1016/s1470-2045(18)30261-4 (opens in a new tab)

147. 147.
     Innate and adaptive immune traits are differentially affected by genetic and environmental factors · 2017

     No notice
148. 148.

     Orrù V, Steri M, Sole G, Sidore C, Virdis F, Dei M, Lai S, Zoledziewska M, Busonero F, Mulas A, et al. Genetic variants regulating immune cell levels in health and disease. Cell. 2013;155:242-256.

     Not in our library10.1016/j.cell.2013.08.041 (opens in a new tab)

149. 149.

     Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, et al. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021;54:367-386.

     Not in our library10.1016/j.immuni.2021.01.011 (opens in a new tab)

150. 150.

     Shahamatdar S, He MX, Reyna MA, Gusev A, AlDubayan SH, Van Allen EM, Ramachandran S. Germline features associated with immune infiltration in solid tumors. Cell Rep. 2020;30:2900-2908.

     Not in our library10.1016/j.celrep.2020.02.039 (opens in a new tab)

151. 151.

     Pagadala M, Sears TJ, Wu VH, Pérez-Guijarro E, Kim H, Castro A, Talwar JV, Gonzalez-Colin C, Cao S, Schmiedel BJ, et al. Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response. Nat Commun. 2023;14.

     Not in our library10.1038/s41467-023-38271-5 (opens in a new tab)

152. 152.

     Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, Morris LGT, Riaz N, Lenz TL, Chan TA. Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019;25:1715-1720.

     Not in our library10.1038/s41591-019-0639-4 (opens in a new tab)

153. 153.

     Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359:582-587.

     Not in our library10.1126/science.aao4572 (opens in a new tab)

154. 154.

     Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199:3360-3368.

     Not in our library10.4049/jimmunol.1700893 (opens in a new tab)

155. 155.

     Marty R, Kaabinejadian S, Rossell D, Slifker MJ, van de Haar J, Engin HB, de Prisco N, Ideker T, Hildebrand WH, Font-Burgada J, et al. MHC-I genotype restricts the oncogenic mutational landscape. Cell. 2017;171:1272-1283.

     Not in our library10.1016/j.cell.2017.09.050 (opens in a new tab)

156. 156.

     Mandel P, Metais P. Les acides nucléiques du plasma sanguine chez l’homme. C R Seances Soc Biol Fil. 142;241-243.

     Not in our library

157. 157.

     Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao S-L, Fhv M, Djb M. Soluble Normal and Mutated DNA Sequences from Single-Copy Genes in Human Blood. Cancer Epidemiol Biomarkers Prev. 1994;3:67-71.

     Not in our library

158. 158.

     Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6.

     Not in our library10.1126/scitranslmed.3007094 (opens in a new tab)

159. 159.

     Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, Rosenthal R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446-451.

     Not in our library10.1038/nature22364 (opens in a new tab)

160. 160.

     McEvoy AC, Warburton L, Al-Ogaili Z, Celliers L, Calapre L, Pereira MR, Khattak MA, Meniawy TM, Millward M, Ziman M, et al. Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer. 2018;18:1-8.

     Not in our library10.1186/s12885-018-4637-6 (opens in a new tab)

161. 161.

     Chabon JJ, Hamilton EG, Kurtz DM, Esfahani MS, Moding EJ, Stehr H, Schroers-Martin J, Nabet BY, Chen B, Chaudhuri AA, et al. Integrating genomic features for non-invasive early lung cancer detection. Nat. 2020;580(7802):245-251.

     Not in our library10.1038/s41586-020-2140-0 (opens in a new tab)

162. 162.
     Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA · 2023

     No notice
163. 163.

     Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25:4691-4700.

     Not in our library10.1158/1078-0432.ccr-19-0624 (opens in a new tab)

164. 164.

     Nakamura Y, Taniguchi H, Ikeda M, Bando H, Kato K, Morizane C, Esaki T, Komatsu Y, Kawamoto Y, Takahashi N, et al. Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med. 2020;26(12):1859-1864.

     Not in our library10.1038/s41591-020-1063-5 (opens in a new tab)

165. 165.

     Shinozaki M, O’Day SJ, Kitago M, Amersi F, Kuo C, Kim J, Wang HJ, Hoon DSB. Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy. Clin Cancer Res. 2007;13:2068-2074.

     Not in our library10.1158/1078-0432.ccr-06-2120 (opens in a new tab)

166. 166.

     Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990.

     Not in our library10.1038/nm.1789 (opens in a new tab)

167. 167.

     Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, Gillet B, Gongora C, Dechelotte P, Robert B, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20(4):430-435.

     Not in our library10.1038/nm.3511 (opens in a new tab)

168. 168.

     Jenkins S, Yang JCH, Ramalingam SS, Yu K, Patel S, Weston S, Hodge R, Cantarini M, Jänne PA, Mitsudomi T, et al. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer. J Thorac Oncol. 2017;12:1061-1070.

     Not in our library10.1016/j.jtho.2017.04.003 (opens in a new tab)

169. 169.

     Summary of safety and effectiveness data (SSED), Guardant360® CDx. 2020;P200010.

     Not in our library

170. 170.

     Summary of safety and effectiveness data (SSED), FoundationOne® Liquid CDx. 2020;P190032.

     Not in our library

171. 171.

     Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, et al. Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. J Mol Diagnostics. 2018;20:686-702.

     Not in our library10.1016/j.jmoldx.2018.05.004 (opens in a new tab)

172. 172.

     Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, Razavi P, Reis-Filho JS, Shen R, Isbell JM, et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann Oncol. 2019;30:597-603.

     Not in our library10.1093/annonc/mdz046 (opens in a new tab)

173. 173.

     Odegaard JI, Vincent JJ, Mortimer S, Vowles JV, Ulrich BC, Banks KC, Fairclough SR, Zill OA, Sikora M, Mokhtari R, et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue-and plasma-based methodologies. Clin Cancer Res. 2018;24:3539-3549.

     Not in our library10.1158/1078-0432.ccr-17-3831 (opens in a new tab)

174. 174.

     Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, et al. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. JNCI J Natl Cancer Inst. 2017;109.

     Not in our library10.1093/jnci/djx118 (opens in a new tab)

175. 175.
     Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors · 2017

     No notice
176. 176.

     Zill OA, Banks KC, Fairclough SR, Mortimer SA, Vowles JV, Mokhtari R, Gandara DR, Mack PC, Odegaard JI, Nagy RJ, et al. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin Cancer Res. 2018;24:3528-3538.

     Not in our library10.1158/1078-0432.ccr-17-3837 (opens in a new tab)

177. 177.

     Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer. JAMA Oncol. 2019;5:173-180.

     Not in our library10.1001/jamaoncol.2018.4305 (opens in a new tab)

178. 178.
     Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial · 2020

     No notice
179. 179.
     Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial · 2021

     No notice
180. 180.

     Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33:750-768.

     Not in our library10.1016/j.annonc.2022.05.520 (opens in a new tab)

181. 181.

     Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Bivona T, Diehn M, Dive C, Dziadziuszko R, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021;16:1647-1662.

     Not in our library10.1016/j.jtho.2021.06.017 (opens in a new tab)

182. 182.
     Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients · 2016

     Corrected
183. 183.
     Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel · 2019

     No notice
184. 184.

     Thress KS, Paweletz CP, Felip E, Cho BC, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21(6):560-562.

     Not in our library10.1038/nm.3854 (opens in a new tab)

185. 185.

     Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res. 2019;25:7035-7045.

     Not in our library10.1158/1078-0432.ccr-19-1324 (opens in a new tab)

186. 186.

     Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441-1448.

     Not in our library10.1038/s41591-018-0134-3 (opens in a new tab)

187. 187.
     Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer · 2018

     No notice
188. 188.

     Anagnostou V, Forde PM, White JR, Niknafs N, Hruban C, Naidoo J, Marrone K, Ashok Sivakumar IK, Bruhm DC, Rosner S, et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer. Cancer Res. 2019;79:1214-1225.

     Not in our library10.1158/0008-5472.can-18-1127 (opens in a new tab)

189. 189.

     Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449-1458.

     Not in our library10.1038/s41591-018-0101-z (opens in a new tab)

190. 190.

     Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28:1130-1136.

     Not in our library10.1093/annonc/mdx026 (opens in a new tab)

191. 191.

     Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, Tacey M, Wong R, Singh M, Karapetis CS, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. N Ann Oncol. 2015;26:1715-1722.

     Not in our library10.1093/annonc/mdv177 (opens in a new tab)

192. 192.

     Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, et al. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020;183:363-376.

     Not in our library10.1016/j.cell.2020.09.001 (opens in a new tab)

193. 193.

     Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1(9):873-881.

     Not in our library10.1038/s43018-020-0096-5 (opens in a new tab)

194. 194.

     Anagnostou V, Ho C, Wheatley-Price P, Laurie S, Taylor J, Sacher A, Brahmer J, Gallinaro L, Ding K, Dancey J. FP05.02 A Biomarker-Directed, Multi-Center Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Lung Cancer. J Thorac Oncol. 2021;16:S952.

     Not in our library10.1016/j.jtho.2021.08.219 (opens in a new tab)

195. 195.

     Isbell JM, Li BT, Razavi P, Reis-Filo J, Liu S-Y, Selenica P, Adusumilli P, Bott M, Jones DR, Rusch VW, et al. Abstract 3375: Ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq. Cancer Res. 2023;83:3375.

     Not in our library10.1158/1538-7445.am2023-3375 (opens in a new tab)

196. 196.

     Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, Schultz A, Jin MC, Scherer F, Garofalo A, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39(12):1537-1547.

     Not in our library10.1038/s41587-021-00981-w (opens in a new tab)

197. 197.

     Moding EJ, Nabet BY, Alizadeh AA, Diehn M. Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease. Cancer Discov. 2021;11:2968-2986.

     Not in our library10.1158/2159-8290.cd-21-0634 (opens in a new tab)

198. 198.

     Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7:1394-1403.

     Not in our library10.1158/2159-8290.cd-17-0716 (opens in a new tab)

199. 199.

     Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7.

     Not in our library10.1126/scitranslmed.aab0021 (opens in a new tab)

200. 200.

     Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, et al. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. JAMA Oncol. 2019;5:1473-1478.

     Not in our library10.1001/jamaoncol.2019.1838 (opens in a new tab)

201. 201.
     Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease · 2015

     No notice
202. 202.

     Tarazona N, Gimeno-Valiente F, Gambardella V, Zuñiga S, Rentero-Garrido P, Huerta M, Roselló S, Martinez-Ciarpaglini C, Carbonell-Asins JA, Carrasco F, et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019;30:1804-1812.

     Not in our library10.1093/annonc/mdz390 (opens in a new tab)

203. 203.

     Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. N Engl J Med. 2022;386:2261-2272.

     Not in our library10.1056/nejmoa2200075 (opens in a new tab)

204. 204.
     Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer · 2023

     No notice
205. 205.

     Zhou C, Das Thakur M, Srivastava MK, Zou W, Xu H, Ballinger M, Felip E, Wakelee H, Altorki NK, Reck M, et al. 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Ann Oncol. 2021;32:S1374.

     Not in our library10.1016/j.annonc.2021.10.018 (opens in a new tab)

206. 206.

     Zhang JT, Liu SY, Gao W, Liu SYM, Yan HH, Ji L, Chen Y, Gong Y, Lu HL, Lin JT, et al. Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer. Cancer Discov. 2022;12:1690-1701.

     Not in our library10.1158/2159-8290.cd-21-1486 (opens in a new tab)

207. 207.

     Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, Chung G, Clement J, Gao J, Hunkapiller N, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32:1167-1177.

     Not in our library10.1016/j.annonc.2021.05.806 (opens in a new tab)

208. 208.

     Lennon AM, Buchanan AH, Kinde I, Warren A, Honushefsky A, Cohain AT, Ledbetter DH, Sanfilippo F, Sheridan K, Rosica D, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science (80-. ). 2020;9601:eabb9601.

     Not in our library10.1126/science.abb9601 (opens in a new tab)

209. 209.

     Burgener JM, Zou J, Zhao Z, Zheng Y, Shen SY, Huang SH, Keshavarzi S, Xu W, Liu F-F, Liu G, et al. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021.

     Not in our library10.1158/1078-0432.ccr-21-0110 (opens in a new tab)

210. 210.
     Detection and characterization of lung cancer using cell-free DNA fragmentomes · 2021

     No notice
211. 211.

     Chen X, Dong Z, Hubbell E, Kurtzman KN, Oxnard GR, Venn O, Melton C, Clarke CA, Shaknovich R, Ma T, et al. Prognostic significance of blood-based multi-cancer detection in plasma cell-free DNA. Clin Cancer Res. 2021;27:4221-4229.

     Not in our library10.1158/1078-0432.ccr-21-0417 (opens in a new tab)

212. 212.

     Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513.

     Not in our library10.1073/pnas.0804549105 (opens in a new tab)

213. 213.

     Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: a new source of biomarkers. Mutat Res. 2011;717:85.

     Not in our library10.1016/j.mrfmmm.2011.03.004 (opens in a new tab)

214. 214.

     Metzenmacher M, Váraljai R, Hegedüs B, Cima I, Forster J, Schramm A, Scheffler B, Horn PA, Klein CA, Szarvas T, et al. Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. Cancers (Basel). 2020;12:353.

     Not in our library10.3390/cancers12020353 (opens in a new tab)

215. 215.
     A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection · 2021

     Corrected
216. 216.

     Vorperian SK, Moufarrej MN, Jones RC, Karkanias J, Krasnow M, Oliveira Pisco A, Quake SR, Salzman J, Yosef N, Bulthaup B, et al. Cell types of origin of the cell-free transcriptome. Nat Biotechnol. 2022;40(6):855-861.

     Not in our library10.1038/s41587-021-01188-9 (opens in a new tab)

217. 217.

     Ren AH, Diamandis EP, Kulasingam V. Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification. Mol Cell Proteomics. 2021;20:100155.

     Not in our library10.1016/j.mcpro.2021.100155 (opens in a new tab)

218. 218.

     Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res. 2011;39:e102.

     Not in our library10.1093/nar/gkr424 (opens in a new tab)

219. 219.

     Mehan MR, Ostroff R, Wilcox SK, Steele F, Schneider D, Jarvis TC, Baird GS, Gold L, Janjic N. Highly multiplexed proteomic platform for biomarker discovery, diagnostics, and therapeutics. Adv Exp Med Biol. 2013;734:283-300.

     Not in our library10.1007/978-1-4614-4118-2_20/figures/7 (opens in a new tab)

220. 220.

     Álvez MB, Edfors F, von Feilitzen K, Zwahlen M, Mardinoglu A, Edqvist P-H, Sjöblom T, Lundin E, Rameika N, Enblad G, et al. Next generation pan-cancer blood proteome profiling using proximity extension assay. Nat Commun. 2023;14(1):1-13.

     Not in our library10.1038/s41467-023-39765-y (opens in a new tab)

221. 221.

     Graumann J, Finkernagel F, Reinartz S, Stief T, Brödje D, Renz H, Jansen JM, Wagner U, Worzfeld T, Pogge von Strandmann E, et al. Multi-platform Affinity Proteomics Identify Proteins Linked to Metastasis and Immune Suppression in Ovarian Cancer Plasma. Front Oncol. 2019;9:491508.

     Not in our library10.3389/fonc.2019.01150/bibtex (opens in a new tab)

222. 222.

     Blatt S, Kämmerer PW, Krüger M, Surabattula R, Thiem DGE, Dillon ST, Al-Nawas B, Libermann TA, Schuppan D. High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma. Cancers (Basel). 2023;15:2071.

     Not in our library10.3390/cancers15072071/s1 (opens in a new tab)

Cited by papers we hold 2

• Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives · 2025
  Not checked
• Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells · 2024
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.